PharmacoEconomics (2013) 31:25–48 DOI 10.1007/s40273-012-0008-3
SYSTEMATIC REVIEW
A Systematic and Critical Review of the Evolving Methods and Applications of Value of Information in Academia and Practice Lotte Steuten • Gijs van de Wetering • ` Karin Groothuis-Oudshoorn • Valesca Retel
Published online: 4 December 2012 Ó Springer International Publishing Switzerland 2012
Abstract Objective This article provides a systematic and critical review of the evolving methods and applications of value of information (VOI) in academia and practice and discusses where future research needs to be directed. Methods Published VOI studies were identified by conducting a computerized search on Scopus and ISI Web of Science from Therefore, this paper introduces the concept of VOI in a non-theoretical way and provides a systematic and critical review of the evolving methods and applications of VOI in academia and practice.
2 VOI Analysis To the extent that decision making between alternative courses of action in healthcare is based on evidence regarding clinical and cost effectiveness and aims to maximize net health benefit, at decision time, any decision maker will (or should) ask himself: Is the current evidence base regarding the clinical and cost effectiveness of this medical technology or treatment sufficiently certain for the
L. Steuten et al.
decision I’m about to make today? And what are the consequences of an uncertain, and thus potentially wrong, decision? Would postponing the decision to await further evidence increase or decrease the net benefit of healthcare to society? VOI analysis helps to answer these questions as it can explicitly and quantitatively inform two related decisions, by using specific VOI methods for each [1, 7]. The first decision is whether to adopt a health technology given existing evidence; the second decision is whether more information is required to support this decision in the future [8]. VOI analysis is based on the
Related Documents: pharmacoeconomic Essay examples
Rituximab as a Treatment for Non Hodgkin’s Lymphoma LIB 100, M11 Avalon Adams Professor Khan Spring 2014 Topic: Rituximab as a Treatment for Non Hodgkin’s Lymphoma Thesis: Rituximab is a medication, when used helps fights off cancer and tries to restore the normal cycle of a lymphocyte. Selection and Evaluation of Sources: For my first source I used the entry on New developments in the management of diffuse large B cell Lymphoma written by Thomas M. Habermann. I…
Zero-Based Budgeting MHA 612 Dr. Kathy Wood October 14th, 2013 Zero-Based Budgeting Introduction As the zero-based budget consultant for Windsor Memorial Hospital I will make recommendations to the Board of Directors on how to create a solid plan to reduce costs and increase productivity. This will be a team based solution. In order to sustain the plan for years to come, it will require continued effort and a commitment from all current and future employees. Zero-based budgeting…
Volume 12 • Number 8 • 2009 VA L U E I N H E A LT H Comparative Analysis of Length of Stay,Total Costs, and Treatment Success between Intravenous Moxifloxacin 400 mg and Levofloxacin 750 mg among Hospitalized Patients with Community-Acquired Pneumonia vhe_576 1135..1143 Howard Friedman, PhD,1 Xue Song, PhD,2 Simone Crespi, MPH,3 Prakash Navaratnam, MPH, PhD4 1 Analytic Solutions, LLC, New York, NY, USA; 2Thomson Reuters Healthcare, Cambridge, MA, USA; 3Schering-Plough Pharmaceuticals…
MANAGERIAL AND DECISION ECONOMICS Manage. Decis. Econ. 28: 469–479 (2007) Published online in Wiley InterScience (www.interscience.wiley.com) DOI: 10.1002/mde.1360 The Cost of Biopharmaceutical R&D: Is Biotech Different? Joseph A. DiMasia,* and Henry G. Grabowskib a Tufts Center for the Study of Drug Development, Tufts University, USA b Department of Economics, Duke University, USA The costs of developing the types of new drugs that have been pursued by traditional pharmaceutical…